• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Analysis of controlled ovarian hyperstimulation protocols in women over 35 years old with poor ovarian response: a real-world study.对卵巢反应不良的 35 岁以上高龄妇女控制性卵巢过度刺激方案的分析:一项真实世界研究。
BMC Pregnancy Childbirth. 2023 Nov 23;23(1):813. doi: 10.1186/s12884-023-06112-4.
2
Efficacies of different ovarian hyperstimulation protocols in elderly patients with poor ovarian response.不同卵巢刺激方案在卵巢低反应高龄患者中的疗效。
Eur Rev Med Pharmacol Sci. 2023 Dec;27(23):11606-11613. doi: 10.26355/eurrev_202312_34599.
3
[Cumulative live birth rates per oocytes retrieved cycle: evaluation of clinical outcomes of IVF/ICSI].[每个取卵周期的累积活产率:体外受精/卵胞浆内单精子注射临床结局评估]
Zhonghua Fu Chan Ke Za Zhi. 2018 Mar 25;53(3):160-166. doi: 10.3760/cma.j.issn.0529-567X.2018.03.004.
4
Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.促性腺激素释放激素(GnRH)拮抗剂方案与GnRH激动剂方案中严重卵巢过度刺激综合征的风险:一项纳入1050个首次体外受精/卵胞浆内单精子注射周期的随机对照试验
Hum Reprod. 2016 Jun;31(6):1253-64. doi: 10.1093/humrep/dew051. Epub 2016 Apr 8.
5
Cumulative live birth rates after one ART cycle including all subsequent frozen-thaw cycles in 1050 women: secondary outcome of an RCT comparing GnRH-antagonist and GnRH-agonist protocols.1050名女性在一个辅助生殖技术周期(包括所有后续冻融周期)后的累积活产率:一项比较促性腺激素释放激素拮抗剂和促性腺激素释放激素激动剂方案的随机对照试验的次要结果。
Hum Reprod. 2017 Mar 1;32(3):556-567. doi: 10.1093/humrep/dew358.
6
Flexible GnRH Antagonist Protocol versus Progestin-primed Ovarian Stimulation (PPOS) Protocol in Patients with Polycystic Ovary Syndrome: Comparison of Clinical Outcomes and Ovarian Response.多囊卵巢综合征患者中采用灵活 GnRH 拮抗剂方案与孕激素预刺激卵巢刺激(PPOS)方案:临床结局和卵巢反应的比较。
Curr Med Sci. 2019 Jun;39(3):431-436. doi: 10.1007/s11596-019-2055-x. Epub 2019 Jun 17.
7
In-vitro maturation of oocytes vs in-vitro fertilization with a gonadotropin-releasing hormone antagonist for women with polycystic ovarian syndrome: can superiority be defined?多囊卵巢综合征女性卵母细胞体外成熟与促性腺激素释放激素拮抗剂体外受精的比较:能否确定优势?
Eur J Obstet Gynecol Reprod Biol. 2014 Aug;179:46-50. doi: 10.1016/j.ejogrb.2014.05.013. Epub 2014 Jun 2.
8
Cumulative live birth rates between GnRH-agonist long and GnRH-antagonist protocol in one ART cycle when all embryos transferred: real-word data of 18,853 women from China.在中国,一项 ART 周期中所有胚胎移植时,促性腺激素释放激素激动剂长方案与拮抗剂方案的累积活产率:来自中国的 18853 名女性的真实数据。
Reprod Biol Endocrinol. 2021 Aug 12;19(1):124. doi: 10.1186/s12958-021-00814-0.
9
The depot GnRH agonist protocol improves the live birth rate per fresh embryo transfer cycle, but not the cumulative live birth rate in normal responders: a randomized controlled trial and molecular mechanism study.促性腺激素释放激素激动剂扳机方案可提高新鲜胚胎移植周期的活产率,但不能提高正常反应者的累积活产率:一项随机对照试验及分子机制研究。
Hum Reprod. 2020 Jun 1;35(6):1306-1318. doi: 10.1093/humrep/deaa086.
10
The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.在接受体外受精的高危患者中,促性腺激素释放激素(GnRH)激动剂与GnRH拮抗剂联合治疗后用于诱导卵母细胞成熟可预防卵巢过度刺激综合征的风险:一项前瞻性随机对照研究。
Fertil Steril. 2008 Jan;89(1):84-91. doi: 10.1016/j.fertnstert.2007.02.002. Epub 2007 Apr 26.

引用本文的文献

1
Intra-ovarian injection of autologous menstrual blood-derived-mesenchymal stromal cells: a safe and promising method to improve pregnancy rate in poor ovarian responders.卵巢内注射自体月经血来源的间充质基质细胞:一种提高卵巢反应不良患者妊娠率的安全且有前景的方法。
Stem Cell Res Ther. 2025 Apr 12;16(1):171. doi: 10.1186/s13287-025-04278-6.
2
Reproductive Health in Women with Major β-Thalassemia: Evaluating Ovarian Reserve and Endocrine Complications.重型β地中海贫血女性的生殖健康:评估卵巢储备和内分泌并发症
Metabolites. 2024 Dec 20;14(12):717. doi: 10.3390/metabo14120717.

本文引用的文献

1
Maternal age and miscarriage: A unique association curve in Sudan.产妇年龄与流产:苏丹的独特关联曲线。
Afr J Reprod Health. 2022 Jul;26(7):15-21. doi: 10.29063/ajrh2022/v26i7.2.
2
Comparison of pregnancy outcome after fresh embryo transfer between GnRH antagonist and GnRH agonist regimens in patients with thin endometrium.薄子宫内膜患者中,GnRH拮抗剂方案与GnRH激动剂方案新鲜胚胎移植后的妊娠结局比较。
Front Med (Lausanne). 2023 Jan 19;10:1071014. doi: 10.3389/fmed.2023.1071014. eCollection 2023.
3
Regulation of ovarian function by growth hormone: Potential intervention of ovarian aging.生长激素对卵巢功能的调节:干预卵巢衰老的潜力。
Front Endocrinol (Lausanne). 2023 Jan 9;13:1072313. doi: 10.3389/fendo.2022.1072313. eCollection 2022.
4
Comparison of clinical effects between early follicular prolonged GnRH agonist protocol and GnRH antagonist protocol in 3310 cycles: a retrospective study.早卵泡期延长 GnRH 激动剂方案与 GnRH 拮抗剂方案在 3310 个周期中的临床效果比较:一项回顾性研究。
BMC Pregnancy Childbirth. 2022 Dec 15;22(1):942. doi: 10.1186/s12884-022-05295-6.
5
Growth hormone in fertility and infertility: Mechanisms of action and clinical applications.生长激素在生育和不育中的作用:作用机制及临床应用。
Front Endocrinol (Lausanne). 2022 Nov 14;13:1040503. doi: 10.3389/fendo.2022.1040503. eCollection 2022.
6
Prediction model of gonadotropin starting dose and its clinical application in controlled ovarian stimulation.促性腺激素起始剂量预测模型及其在控制性卵巢刺激中的临床应用。
BMC Pregnancy Childbirth. 2022 Nov 4;22(1):810. doi: 10.1186/s12884-022-05152-6.
7
GnRH Antagonist Protocol Versus GnRH Agonist Long Protocol: A Retrospective Cohort Study on Clinical Outcomes and Maternal-Neonatal Safety.促性腺激素释放激素拮抗剂方案与促性腺激素释放激素激动剂长方案:临床结局和母婴安全性的回顾性队列研究。
Front Endocrinol (Lausanne). 2022 Jun 29;13:875779. doi: 10.3389/fendo.2022.875779. eCollection 2022.
8
Follicular-Phase GnRH Agonist Protocol Is Another Choice for Polycystic Ovary Syndrome Patients With Lower LH/FSH and Lower AMH Levels Without Increasing Severe OHSS Risk.卵泡期 GnRH 激动剂方案是 LH/FSH 较低和 AMH 水平较低的多囊卵巢综合征患者的另一种选择,不会增加严重 OHSS 风险。
Front Endocrinol (Lausanne). 2022 Jun 10;13:905263. doi: 10.3389/fendo.2022.905263. eCollection 2022.
9
GnRH Agonist and hCG (Dual Trigger) Versus hCG Trigger for Final Oocyte Maturation in Expected Normal Responders With a High Immature Oocyte Rate: Study Protocol for a Randomized, Superiority, Parallel Group, Controlled Trial.GnRH 激动剂联合 hCG(双重扳机)与 hCG 扳机在高未成熟卵比率的预计正常反应者中用于卵母细胞最终成熟的比较:一项随机、优效性、平行组、对照试验的研究方案。
Front Endocrinol (Lausanne). 2022 Mar 28;13:831859. doi: 10.3389/fendo.2022.831859. eCollection 2022.
10
Effect of rLH Supplementation during Controlled Ovarian Stimulation for IVF: Evidence from a Retrospective Analysis of 1470 Poor/Suboptimal/Normal Responders Receiving Either rFSH plus rLH or rFSH Alone.在体外受精控制性卵巢刺激过程中补充重组促黄体生成素的效果:来自对1470名接受重组促卵泡素加重组促黄体生成素或仅接受重组促卵泡素的低反应/反应欠佳/正常反应者的回顾性分析的证据。
J Clin Med. 2022 Mar 13;11(6):1575. doi: 10.3390/jcm11061575.

对卵巢反应不良的 35 岁以上高龄妇女控制性卵巢过度刺激方案的分析:一项真实世界研究。

Analysis of controlled ovarian hyperstimulation protocols in women over 35 years old with poor ovarian response: a real-world study.

机构信息

Department of Gynaecology and obstetrics, The First People's Hospital of Shangqiu, 292 Kaixuan South Road, Henan, Shangqiu, People's Republic of China.

Graduate School of Zhengzhou University, Henan, People's Republic of China.

出版信息

BMC Pregnancy Childbirth. 2023 Nov 23;23(1):813. doi: 10.1186/s12884-023-06112-4.

DOI:10.1186/s12884-023-06112-4
PMID:37996795
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10666416/
Abstract

The objective of this study was to investigate the optimal controlled ovarian hyperstimulation (COH) protocol for patients aged 35 and above with poor ovarian response (POR), utilizing real-world data. This retrospective cohort study examined clinical information from a total of 4256 patients between January 2017 and November 2022. The patients were categorized into three groups: modified GnRH agonist protocol (2116 patients), GnRH antagonist protocol (1628 patients), and Mild stimulation protocol (512 patients). Comparative analysis was conducted on clinical variables and pregnancy outcomes across the three groups. The GnRH agonist protocol was associated with a higher number of oocyte number (4.02 ± 2.25 vs. 3.15 ± 1.52 vs. 2.40 ± 1.26, p < 0.001), higher number of transferable embryos (1.73 ± 1.02 vs. 1.35 ± 1.22 vs. 1.10 ± 0.86, p = 0.016), higher cumulative live birth rate 28.50(603/2116) vs. 24.94(406/1628) vs. 20.51(105/512), p < 0.001) than GnRH antagonist protocol and Mild stimulation protocol, the Mild stimulation protocol was associated with a higher miscarriage rates 16.27(62/381) vs. 16.61(48/289) vs. 32.22(29/90), p = 0.001) than the other two groups. Therefore, it can be concluded that all three protocols can be used in patients over 35 years old with poor ovarian response. However, if patients require more frozen-thawed embryo transfers to achieve better cumulative live birth rates, the modified GnRH agonist protocol may be the preferable option.

摘要

本研究旨在利用真实世界数据探讨 35 岁及以上卵巢低反应(POR)患者的最佳控制性卵巢刺激(COH)方案。这项回顾性队列研究分析了 2017 年 1 月至 2022 年 11 月期间共 4256 名患者的临床信息。患者分为三组:改良 GnRH 激动剂方案(2116 例)、GnRH 拮抗剂方案(1628 例)和温和刺激方案(512 例)。对三组的临床变量和妊娠结局进行了比较分析。GnRH 激动剂方案与更多的卵母细胞数(4.02±2.25 比 3.15±1.52 比 2.40±1.26,p<0.001)、更多可移植胚胎数(1.73±1.02 比 1.35±1.22 比 1.10±0.86,p=0.016)和更高的累积活产率 28.50(603/2116)比 GnRH 拮抗剂方案和温和刺激方案(24.94[406/1628]比 20.51[105/512],p<0.001)相关,而温和刺激方案与更高的流产率 16.27(62/381)比 GnRH 拮抗剂方案和温和刺激方案(16.61[48/289]比 32.22[29/90],p=0.001)相关。因此,可以得出结论,对于卵巢低反应的 35 岁以上患者,三种方案均可使用。然而,如果患者需要更多的冻融胚胎移植来提高累积活产率,改良 GnRH 激动剂方案可能是更好的选择。